You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 6, 2011

Beating Cosmetic Product Registration Hurdles

Bangkok Post, Corporate Counsellor Column

On January 1, 2008, Asean member countries implemented the Asean Harmonization Cosmetics Regulation Scheme in order to harmonize a previously chaotic process. A multitude of confusing laws and procedures has now been transformed into a streamlined system with just a single category for cosmetic products and an efficient registration process.

The Thai Food and Drug Administration (FDA) implemented a new online cosmetic product registration system on November 1, 2010. Registration is now less time consuming and more environmentally friendly than under the previous paper-based system.

The FDA has also created a single product category, which forces some cosmetic companies to re-register their products. This is an important change from past practice, when there were three categories for cosmetic products.

According to the Society of Cosmetic Chemists of Thailand, the local cosmetic industry has been growing by 10 to 20 percent per year over the last ten years and is expected to see 30 percent growth in the domestic market in 2011. This domestic trend mirrors similar rapid growth in cosmetic imports.

Clearly, Thailand is becoming an extremely attractive place for cosmetic product distributors to do business. As the industry continues to expand, cosmetics distributors new to the market should be aware of possible hurdles that typically arise during the FDA product registration process. By preparing effectively, applicants will be able to save costs and bring their products to market quickly.

Product Name

Cosmetic products rely mainly on the name of the product to attract consumers. This has proven to be a very effective method for marketing the products, since this is the first element that consumers look at when electing to purchase a product.

Therefore, distributors need to take the utmost care when naming their products, prior to applying for product registration in Thailand. To avoid rejection by the FDA, each word in the product name must correctly reflect the objective of the product, and the words used must not mislead consumers.

One difficulty faced by companies is using product names that differ from the ingredients or the purpose of the product. For example, if the product name is “TRADENAME Tanning Body Lotion” but the product formula contains no ingredients that act as a tanning agent, this product will be declined registration by the FDA.

The manufacturer or importer must also exercise care in regard to the choice of a product name to avoid it being deemed an overclaim or use of homophonous words.

For example, a product used to combat wrinkles is called “TRADENAME Eraser Wrinkle Serum”. The word “eraser” will not be permitted for use in the product name because, in reality, the product cannot erase wrinkles. FDA officials would therefore deem the product name to be an overclaim.

Use of a homophonous word for a prohibited or improper word in a product name is also impermissible. An example of this is “Btox”, which is derived from the prohibited word “Botox”. “Btox” would be denied registration by the FDA because it is confusingly similar to the registered trademark BOTOX and is deemed an infringement.

Finally, scientific words such as “nano” are not recommended, as additional scientific or reliable supporting documents for those words must be submitted to the FDA to support the claimed correlation.

Formula

The use of a prohibited ingredient in a formula will definitely lead to a rejection by the FDA, and the manufacturer will be required to alter the product formula to secure FDA approval. Examples of prohibited ingredients commonly found in cosmetics are dimethylamine and diethylene glycol.

Some ingredients are authorized but restricted, and these ingredients are thus required to comply with special FDA rules. For example, a hair product formula for curling or straightening hair must not include tetraborates in an amount exceeding 8 percent, whereas a bath product formula must not exceed 18 percent (both are calculated in boric acid form).

A formula containing some specially controlled ingredients, especially natural extracts, must have a product safety document. For example, Citrus Reticulata Peel oil has no restrictions on the amount used in a formula. However, the total concentration of furocoumarin (found in this extract) in a finished cosmetic product must not exceed 1 ppm. Therefore, the company must certify the safety assessment of the product and provide an analysis of the amount of furocoumarin in the finished product.

FDA Cosmetic Category Codes

In the cosmetic registration process, an applicant is required to choose a cosmetic category code for each product from an FDA database known as the “Cosmetic Data Dictionary.”

For example, if the product is a facial makeup set consisting of compact face powder with foundation, sunscreen, and lip gloss, the cosmetic category code would be 12796. If this code is not clearly specified, the characteristics or product type may result in selection of the wrong cosmetic category code, which would lead to the application being rejected by the Examiner.

As the examples above illustrate, it is important that companies pay keen attention to the preparation of the registration of their product and advertising, as this will ensure a smooth and unhindered product launch.

 

RELATED INSIGHTS​ 

February 26, 2026
Laos’ Food and Drug Department (FDD) has been using a new online registration system for drugs since the beginning of the year. The system, which was implemented following the November 2025 issuance of Notice No. 5960/FDD, became the official pathway for submissions on January 1, 2026. Since that date, paper-based registrations have no longer been accepted. This marks a significant advancement in the digitalization of regulatory processes in Laos. As the online system is now the exclusive platform for registration, renewal, and amendments, companies that have not yet aligned their processes to the new system should act promptly to ensure a smooth transition. To assist with this, the FDD will conduct periodic training sessions on the use of the online registration system, which will be delivered either in person or remotely, depending on operator demand. To start using the system, drug and medical device manufacturers, as well as import-export companies, that have not yet registered must submit a formal request identifying the authorized personnel who will access the platform, after which they will be issued user accounts and access codes. Each request must be accompanied by the company’s enterprise registration certificate (incorporation certificate), a copy of the identity card or passport of each designated user, and a scanned copy of their signature. There is no restriction on the number of users per company, allowing flexibility to meet operational needs. Companies that already hold accounts and access codes from the trial phase may continue using them and may apply for additional accounts if needed. Additional Requirements The new system also introduces a standardized format for drug registration numbers. For example, an import drug registration number such as 06 I 4040/15 will be changed to 06-IM-04040-15, and a domestic drug registration number such as 06 L 4040/15 will be changed to
January 21, 2026
Spurred by global geopolitics and Canada’s Indo-Pacific Strategy, which aims to forge deeper ties with ASEAN, Canadian companies have been showing growing interest in Thailand and Southeast Asia in recent years. To understand the opportunities offered by the region, we sat down with Andrew Stoutley, a Toronto native and the chief operating officer of Tilleke & Gibbins, a leading Southeast Asian regional law firm with over 130 years of history in Thailand. Q: Why are Canadian companies looking at Thailand and Southeast Asia right now? A: Two reasons stand out. First, diversification has moved up the agenda. Many Canadian companies want options outside North America due to tariff volatility and policy uncertainty in the United States, as well as questions around the next Canada–United States–Mexico Agreement mandatory joint review. At the same time, the shift of global production from China to Southeast Asia is accelerating, driven by rising costs, geopolitics, and the need to avoid overreliance on a single market. As a result, Canadian companies are looking for a second production base or a regional hub, and Thailand and its neighbors are natural choices given their manufacturing depth, location, and established supply chains. Second, Canada’s own efforts in the region are gaining traction. The Indo-Pacific Strategy has led to more on-the-ground support, including larger trade missions, upgraded diplomatic posts, and new financing options. Export Development Canada (EDC) now has a presence in Bangkok, giving Canadian companies a direct line to financing and insurance in Thailand. There’s also steady progress on trade frameworks like the recently signed Canada–Indonesia Comprehensive Economic Partnership Agreement (which will come into effect pending domestic procedures), ongoing negotiations of a Canada–ASEAN FTA, and the exciting announcement about the launch of negotiations of a Canada–Thailand FTA. Together, these developments have the potential to make it much easier
January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
January 6, 2026
On December 30, 2025, Thailand’s Electronic Transactions Development Agency (ETDA) notified digital marketplace operators of a consolidated list of “high‑risk products” that are subject to strict monitoring on digital platforms. The list was jointly prepared by the Thai Industrial Standards Institute (TISI) and the Food and Drug Administration (FDA) to guide platform compliance in the initial phase of implementation of the Electronic Transaction Committee’s Notification on Other Measures for Marketplace for Goods with Specific Characteristics under Section 18(2) of the 2022 Royal Decree on Digital Platform Businesses Requiring Notification B.E.2568 (2025). The notice is addressed to operators of digital platform services that function as product marketplaces with specific characteristics laid out in the notification. The ETDA states that the TISI and the FDA are closely monitoring the high‑risk product categories on digital platforms, and the published list serves as the baseline reference for platform screening during the initial phase of the notification’s implementation. High‑Risk Product List The list aggregates categories of products that are illegal to sell online or are otherwise tightly regulated under Thai law, with an emphasis on health-related products, controlled substances, medical devices, and a wide range of industrial products that require certification or compliance with specified Thai Industrial Standards, as detailed below. Prohibited and tightly controlled health products. This includes all categories of modern medicines subject to control other than general household remedies; all categories of controlled herbal products except for over-the-counter herbal products; narcotics; psychotropic substances; and medical devices requiring use in medical facilities or a physician’s prescription. Selected industrial products requiring heightened controls. The list highlights dozens of TISI-regulated items commonly sold online. Examples include pacifiers, rice cookers, electrical wire, food wrap film, crayons, washing machines and dryers, air conditioners, electric cookers and air fryers, water heaters, microwave ovens, LED luminaires, hair dryers